Synthesis and biological evaluation of heterocyclic ring-fused betulinic acid derivatives as novel inhibitors of osteoclast differentiation and bone resorption

Journal of Medicinal Chemistry

Volumn 55, Issue 7, 2012, Pages 3122-3134

  Xu, Jun ^a   Li, Zhenxi ^a   Luo, Jian ^a   Yang, Fan ^a   Liu, Ting ^a   Liu, Mingyao ^a   Qiu, Wen Wei ^a   Tang, Jie ^a  

^a EAST CHINA NORMAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; BETULIC ACID; HETEROCYCLIC COMPOUND;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ASSAY; INHIBITION KINETICS; MOUSE; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOLYSIS;

ACID PHOSPHATASE; ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CATHEPSIN K; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; CRYSTALLOGRAPHY, X-RAY; FEMALE; ISOENZYMES; ISOXAZOLES; MICE; MICE, INBRED C57BL; OSTEOCLASTS; OVARIECTOMY; PYRAZINES; PYRAZOLES; PYRIMIDINES; RANK LIGAND; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; TRITERPENES;

EID: 84859790655     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201540h     Document Type: Article

References (58)

1. Seeman, E.; Delmas, P. D. Bone quality: the material and structural basis of bone strength and fragility N. Engl. J. Med. 2006, 354, 2250-2261
2. Srivastava, S.; Weitzmann, M. N.; Kimble, R. B.; Rizzo, M.; Zahner, M.; Milbrandt, J.; Ross, F. P.; Pacifici, R. Estrogen blocks M-CSF gene expression and osteoclast formation by regulating phosphorylation of Egr-1 and its interaction with Sp-1 J. Clin. Invest. 1998, 102, 1850-1859
3. Pacifici, R. Cytokines estrogen and postmenopausal osteoporosis: the second decade Endocrinology 1998, 139, 2659-2661
4. Itzmann, M. N.; Pacifici, R. Estrogen regulation of immune cell bone interactions Ann. N.Y. Acad. Sci. 2006, 1068, 256-274
5. Pietschmann, P.; Rauner, M.; Sipos, W.; Kerschan-Schindl, K. Osteoporosis: an age-related and gender-specific disease: a mini-review Gerontology 2009, 55, 3-12
6. Terpos, E.; Efstathiou, E.; Christoulas, D.; Roussou, M.; Katodritou, E.; Dimopoulos, M. A. RANKL inhibition: clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases Expert Opin. Biol. Ther. 2009, 9, 465-479
7. Lipton, A.; Jun, S. RANKL inhibition in the treatment of bone metastases Curr. Opin. Support. Palliat. Care 2008, 2, 197-203
8. Boyce, B. F.; Li, P.; Yao, Z.; Zhang, Q.; Badell, I. R.; Schwarz, E. M.; O'Keefe, R. J.; Xing, L. TNF-alpha and pathologic bone resorption Keio J. Med. 2005, 54, 127-131
9. Jochum, W.; Passegué, E.; Wagner, E. F. AP-1 in mouse development and tumorigenesis Oncogene 2001, 20, 2401-2412
10. Novack, D. V.; Teitelbaum, S. L. The osteoclast: friend or foe? Annu. Rev. Pathol. 2008, 3, 457-484
11. Walsh, N. C.; Gravallwse, E. M. Bone loss in inflammatory arthritis: mechanisms and treatment strategies Curr. Opin. Rheumatol. 2004, 16, 419-427
12. Teitelbaum, S. L. Osteoclasts: culprits in inflammatory osteolysis Arthritis Res. Ther. 2006, 8, 201
13. Mundy, G. R. Osteoporosis and inflammation Nutr. Rev. 2007, 65, S147-151
14. Cetinkaya, M. B.; KoIkçuI, A.; Yanik, F. F.; BaşogÌ lu, T.; Malatyalioglu, E.; Alper, T. Comparison of the effects of transdermal estrogen, oral estrogen, and oral estrogen-progestogen therapy on bone mineral density in postmenopausal women J. Bone Miner. Metab. 2002, 20, 44-48
15. Canderelli, R.; Leccesse, L. A.; Miller, N. L.; Unruh Davidson, J. Benefits of hormone replacement therapy in postmenopausal women J. Am. Acad. Nurse Pract. 2007, 19, 635-641
16. Studd, J. Estrogens as first-choice therapy for osteoporosis prevention and treatment in women under 60 Climacteric 2009, 12, 206-209
17. Ernster, V. L.; Bush, T. L.; Huggins, G. R.; Hulka, B. S.; Kelsey, J. L.; Schottenfeld, D. Benefits and risks of menopausal estrogen and/or progestin hormone use Prev. Med. 1988, 17, 201-223
18. Keller, K. B.; Lemberg, L. Estrogen plus progestin, benefits and risks: the Women's Health Initiative trials Am. J. Crit. Care 2005, 14, 157-160
19. van de Weijer, P. H. Risks of hormone therapy in the 50-59 year age group Maturitas 2008, 60, 59-64
20. Canonico, M.; Scarabin, P. Y. Hormone therapy and risk of venous thromboembolism among postmenopausal women Climacteric 2009, 12 (Suppl. 1) 76-80
21. Russell, R. G.; Watts, N. B.; Ebetino, F. H.; Rogers, M. J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy Osteoporosis Int. 2008, 19, 733-759
22. Arantes, H. P.; Silva, A. G.; Lazaretti-Castro, M. Bisphosphonates in the treatment of metabolic bone diseases Arq. Bras. Endocrinol. Metabol. 2010, 54, 206-212
23. Conte, P.; Guarneri, V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens Oncologist 2004, 9 (Suppl. 4) 28-37
24. Body, J. J. Bisphosphonate safety and tolerability Oncologist 2005, 10, 318-319
25. Filleul, O.; Crompot, E.; Saussez, S. Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases J. Cancer Res. Clin. Oncol. 2010, 136, 1117-1124
26. Abrahamsen, B. Bisphosphonate adverse effects, lessons from large databases Curr. Opin. Rheumatol. 2010, 22, 404-409
27. Mosekilde, L.; Danielsen, C. C.; Søgaard, C. H.; McOsker, J. E.; Wronski, T. J. The anabolic effects of parathyroid hormone on cortical bone mass, dimensions and strength-assessed in a sexually mature, ovariectomized rat model Bone 1995, 16, 223-230
28. Dobnig, H.; Turner, R. T. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells Endocrinology 1995, 136, 3632-3638
29. Neuprez, A.; Reginster, J. Y. Bone-forming agents in the management of osteoporosis Best Pract. Res., Clin. Endocrinol. Metab. 2008, 22, 869-883
30. Cappuzzo, K. A.; Delafuente, J. C. Teriparatide for severe osteoporosis Ann. Pharmacother. 2004, 38, 294-302
31. Miller, P. D. Safety of parathyroid hormone for the treatment of osteoporosis Curr. Osteoporosis Rep. 2008, 6, 12-16
32. Rodan, G. A.; Martin, T. G. Therapetuic approaches to bone disease Science 2000, 289, 1508-1514
33. Boyle, W. J.; Simonet, W. S.; Lacey, D. L. Osteoclast differentiation and activation Nature 2003, 423, 337-342
34. Newman, D. J.; Cragg, G. M.; Snader, K. M. The influence of natural products upon drug discovery Nat. Prod. Rep. 2000, 17, 215-234
35. Newman, D. J.; Cragg, G. M.; Snader, K. M. Natural products as sources of new drugs over the period 1981-2002 J. Nat. Prod. 2003, 66, 1022-1037
36. Takada, Y.; Ichikawa, H.; Badmaev, V.; Aggarwal, B. B. Acetyl-11-keto-beta-boswellic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing NF-kappa B and NF-kappa B-regulated gene expression J. Immunol. 2006, 176, 3127-3140
37. Qiu, S. X.; Dan, C.; Ding, L. S.; Peng, S.; Chen, S. N.; Farnsworth, N. R.; Nolta, J.; Gross, M. L.; Zhou, P. A triterpene glycoside from black cohosh that inhibits osteoclastogenesis by modulating RANKL and TNFalpha signaling pathways Chem. Biol. 2007, 14, 860-869
38. Li, J. F.; Chen, S. J.; Zhao, Y.; Li, J. X. Glycoside modification of oleanolic acid derivatives as a novel class of anti-osteoclast formation agents Carbohydr. Res. 2009, 344, 599-605
39. Li, J. F.; Zhao, Y.; Cai, M. M.; Li, X. F.; Li, J. X. Synthesis and evaluation of a novel series of heterocyclic oleanolic acid derivatives with anti-osteoclast formation activity Eur. J. Med. Chem. 2009, 44, 2796-2806
40. Liu, J.; Shiono, J.; Shimizu, K.; Kukita, A.; Kukita, T.; Kondo, R. Ganoderic acid DM: anti-androgenic osteoclastogenesis inhibitor Bioorg. Med. Chem. Lett. 2009, 19, 2154-2157
41. Li, C.; Yang, Z.; Li, Z.; Ma, Y.; Zhang, L.; Zheng, C.; Qiu, W.; Wu, X.; Wang, X.; Li, H.; Tang, J.; Qian, M.; Li, D.; Wang, P.; Luo, J.; Liu, M. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways J. Bone Miner. Res. 2011, 26, 644-656
42. Xie, F.; Wu, C. F.; Zhang, Y.; Yao, X. S.; Cheung, P. Y.; Chan, A. S.; Wong, M. S. Increase in bone mass and bone strength by Sambucus williamsii Hance in ovariectomized rats Biol. Pharm. Bull. 2005, 28, 1879-1885
43. Mukherjee, P. K.; Saha, K.; Das, J.; Pal, M.; Saha, B. P. Studies on the anti-inflammatory activity of rhizomes of Nelumbo nucifera Planta Med. 1997, 63, 367-369
44. Kashiwada, Y.; Hashimoto, F.; Cosentino, L. M.; Chen, C. H.; Garrett, P. E.; Lee, K. H. Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents J. Med. Chem. 1996, 39, 1016-1017
45. Fulda, S. Betulinic acid: a natural product with anticancer activity Mol. Nutr. Food Res. 2009, 53, 140-146
46. Mullauer, F. B.; Kessler, J. H.; Medema, J. P. Betulinic acid, a natural compound with potent anticancer effects Anti-Cancer Drugs 2010, 21, 215-227
47. Steinkamp-Fenske, K.; Bollinger, L.; Xu, H.; Yao, Y.; Horke, S.; FoIrstermann, U.; Li, H. Reciprocal regulation of endothelial nitric-oxide synthase and NADPH oxidase by betulinic acid in human endothelial cells J. Pharmacol. Exp. Ther. 2007, 322, 836-842
48. Lo, Y. C.; Chang, Y. H.; Wei, B. L.; Huang, Y. L.; Chiou, W. F. Betulinic acid stimulates the differentiation and mineralization of osteoblastic MC3T3-E1 cells: involvement of BMP/Runx2 and beta-catenin signals J. Agric. Food Chem. 2010, 58, 6643-6649
49. Qiu, W. W.; Shen, Q.; Yang, F.; Wang, B.; Zou, H.; Li, J. Y.; Li, J.; Tang, J. Synthesis and biological evaluation of heterocyclic ring-substituted maslinic acid derivatives as novel inhibitors of protein tyrosine phosphatase 1B Bioorg. Med. Chem. Lett. 2009, 19, 6618-6622
50. Urban, M.; Sarek, J.; Kvasnica, M.; Tislerova, I.; Hajduch, M. Triterpenoid pyrazines and benzopyrazines with cytotoxic activity J. Nat. Prod. 2007, 70, 526-532
51. CCDC 853840 contains the supplementary crystallographic data of compound 20 for this paper. These data can be obtained free of charge via http://www.ccdc.cam.ac.uk/cgi-bin/catreq.cgi or by emailing data-request@ccdc. cam.ac.uk or by contacting The Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB2 1EZ, U.K. (fax, +44 1223 336 33).
52. Miyahara, T.; Hayashi, T.; Matsuda, S.; Yamada, R.; Ikeda, K.; Tonoyama, H.; Komiyama, H.; Matsumoto, M.; Nemoto, N.; Sankawa, U. Inhibitory effects of scopadulcic acid B and its derivatives on bone resorption and osteoclast formation in vitro Bioorg. Med. Chem. Lett. 1996, 6, 1037-1042
53. Hayman, A. R.; Jones, S. J.; Boyde, A.; Foster, D.; Colledge, W. H.; Carlton, M. B.; Evans, M. J.; Cox, T. M. Mice lacking tartrate-resistant acid phosphatase (Acp 5) have disrupted endochondral ossification and mild osteopetrosis Development 1996, 122, 3151-3162
54. Hollberg, K.; Hultenby, K.; Hayman, A.; Cox, T.; Andersson, G. Osteoclasts from mice deficient in tartrate-resistant acid phosphatase have altered ruffled borders and disturbed intracellular vesicular transport Exp. Cell Res. 2002, 279, 227-238
55. Vaaraniemi, J.; Halleen, J. M.; Kaarlonen, K.; Ylipahkala, H.; Alatalo, S. L.; Andersson, G.; Kaija, H.; Vihko, P.; Vaananen, H. K. Intracellular machinery for matrix degradation in bone-resorbing osteoclasts J. Bone Miner. Res. 2004, 19, 1432-1440
56. Xia, L.; Kilb, J.; Wex, H.; Li, Z.; Lipyansky, A.; Breuil, V.; Stein, L.; Palmer, J. T.; Dempster, D. W.; BroIme, D. Localization of rat cathepsin K in osteoclasts and resorption pits: inhibition of bone resorption and cathepsin K-activity by peptidyl vinyl sulfones Biol. Chem. 1999, 380, 679-687
57. Rantakokko, J.; Uusitalo, H.; JaImsaI, T.; Tuukkanen, J.; Aro, H. T.; Vuorio, E. Expression profiles of mRNAs for osteoblast and osteoclast proteins as indicators of bone loss in mouse immobilization osteopenia model J. Bone Miner. Res. 1999, 14, 1934-1942
58. Furuyama, N.; Fujisawa, Y. Regulation of collagenolytic cysteine protease synthesis by estrogen in osteoclasts Steroids 2000, 65, 371-378